{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T07:32:12Z","timestamp":1649057532232},"reference-count":32,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.medcli.2013.05.035","type":"journal-article","created":{"date-parts":[[2013,9,6]],"date-time":"2013-09-06T03:46:38Z","timestamp":1378439198000},"page":"442-446","source":"Crossref","is-referenced-by-count":2,"title":["Alteraciones del metabolismo hidrocarbonado en la acromegalia"],"prefix":"10.1016","volume":"141","author":[{"given":"Betina","family":"Biagetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Obiols","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Valladares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorena","family":"Arnez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bel\u00e9n","family":"Dalama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2013.05.035_bib0005","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1023\/A:1009965803750","article-title":"Epidemiology of acromegaly","volume":"2","author":"Holdaway","year":"1999","journal-title":"Pituitary"},{"key":"10.1016\/j.medcli.2013.05.035_bib0010","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1210\/jc.2006-1668","article-title":"High prevalence of pituitary adenomas: A cross-sectional study in the province of Liege, Belgium","volume":"91","author":"Daly","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.medcli.2013.05.035_bib0015","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4158\/EP.7.3.170","article-title":"Longitudinal assessment of economic burden and clinical outcomes in acromegaly","volume":"7","author":"Wilson","year":"2001","journal-title":"Endocr Pract"},{"key":"10.1016\/j.medcli.2013.05.035_bib0020","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/00005792-199409000-00001","article-title":"Acromegaly. Clinical and biochemical features in 500 patients","volume":"73","author":"Ezzat","year":"1994","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.medcli.2013.05.035_bib0025","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1590\/S0100-879X2001001100009","article-title":"Risk factors for glucose intolerance in active acromegaly","volume":"34","author":"Kreze","year":"2001","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.medcli.2013.05.035_bib0030","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1210\/er.2002-0022","article-title":"Systemic complications of acromegaly: Epidemiology, pathogenesis, and management","volume":"25","author":"Colao","year":"2004","journal-title":"Endocr Rev"},{"key":"10.1016\/j.medcli.2013.05.035_bib0035","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1530\/eje.0.1510439","article-title":"Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA)","volume":"151","author":"Mestron","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.medcli.2013.05.035_bib0040","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1210\/er.2008-0027","article-title":"Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects","volume":"30","author":"M\u00f8ller","year":"2009","journal-title":"Endocr Rev"},{"key":"10.1016\/j.medcli.2013.05.035_bib0045","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1530\/EJE-10-1050","article-title":"Diabetes in acromegaly, prevalence, risk factors, and evolution: Data from the French Acromegaly Registry","volume":"164","author":"Fieffe","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.medcli.2013.05.035_bib0050","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1210\/jc.2003-031199","article-title":"Factors influencing mortality in acromegaly","volume":"89","author":"Holdaway","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.medcli.2013.05.035_bib0055","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ghir.2005.02.005","article-title":"The metabolic role of growth hormone in humans with particular reference to fasting","volume":"15","author":"N\u00f8rrelund","year":"2005","journal-title":"Growth Horm IGF Res"},{"key":"10.1016\/j.medcli.2013.05.035_bib0060","doi-asserted-by":"crossref","first-page":"636","DOI":"10.4158\/EP.17.4.636","article-title":"American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly--2011 update: Executive summary","volume":"17","author":"Katznelson","year":"2011","journal-title":"Endocr Pract"},{"key":"10.1016\/j.medcli.2013.05.035_bib0065","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.medcli.2012.07.024","article-title":"Optimizaci\u00f3n del tratamiento m\u00e9dico de la acromegalia","volume":"140","author":"D\u00edez","year":"2013","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.medcli.2013.05.035_bib0070","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1210\/jc.2005-1704","article-title":"Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: Effects on cardiovascular risk factors","volume":"91","author":"Ronchi","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.medcli.2013.05.035_bib0075","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1210\/jc.2008-2332","article-title":"Effects of somatostatin analogs on glucose homeostasis: A metaanalysis of acromegaly studies","volume":"94","author":"Mazziotti","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.medcli.2013.05.035_bib0080","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1365-2265.2011.03996.x","article-title":"Glucose homeostasis in patients with acromegaly treated with surgery or somatostatin analogues","volume":"75","author":"Tzanela","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.medcli.2013.05.035_bib0085","doi-asserted-by":"crossref","unstructured":"Couture E, Bongard V, Maiza JC, Bennet A, Caron P. Glucose status in patients with acromegaly receiving primary treatment with the somatostatin analog lanreotide. Pituitary [Internet]. 2011;15:518-25 [consultado 24 Ene 2012]. Disponible en: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22058008","DOI":"10.1007\/s11102-011-0361-9"},{"key":"10.1016\/j.medcli.2013.05.035_bib0090","doi-asserted-by":"crossref","first-page":"5627","DOI":"10.1210\/jc.2005-0531","article-title":"Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist","volume":"90","author":"J\u00f8rgensen","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.medcli.2013.05.035_bib0095","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.1210\/jc.2007-1234","article-title":"Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly","volume":"92","author":"Neggers","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.medcli.2013.05.035_bib0100","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1530\/eje.1.02112","article-title":"Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: Effect on IGF-I levels, tumor mass, hypertension and glucose tolerance","volume":"154","author":"Colao","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.medcli.2013.05.035_bib0105","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1530\/eje.1.02312","article-title":"Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: Safety and efficacy evaluation from the German Pegvisomant Observational Study","volume":"156","author":"Schreiber","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.medcli.2013.05.035_bib0110","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1210\/jc.2006-2276","article-title":"The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly","volume":"92","author":"Lindberg-Larsen","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"10.1016\/j.medcli.2013.05.035_bib0115","first-page":"S4","article-title":"Executive summary: Standards of medical care in diabetes--2012","volume":"35","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.medcli.2013.05.035_bib0120","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11102-012-0384-x","article-title":"Changes in acromegaly treatment over four decades in Spain: Analysis of the Spanish Acromegaly Registry (REA)","volume":"16","author":"Sesmilo","year":"2013","journal-title":"Pituitary"},{"key":"10.1016\/j.medcli.2013.05.035_bib0125","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1365-2265.1980.tb03132.x","article-title":"An assessment of glucose intolerance in acromegaly and its response to medical treatment","volume":"12","author":"Wass","year":"1980","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.medcli.2013.05.035_bib0130","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s11102-010-0284-x","article-title":"Clinical and biochemical characteristics of acromegalic patients with different abnormalities in glucose metabolism","volume":"14","author":"Espinosa-de-los-Monteros","year":"2011","journal-title":"Pituitary"},{"key":"10.1016\/j.medcli.2013.05.035_bib0135","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1365-2265.1986.tb03630.x","article-title":"Effects of somatostatin analogue SMS 201-995 in non-insulin-dependent diabetes","volume":"25","author":"Davies","year":"1986","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.medcli.2013.05.035_bib0140","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/0016-5085(80)90188-2","article-title":"Effect of intravenous somatostatin on jejunal absorption of glucose, amino acids, water, and electrolytes","volume":"78","author":"Krejs","year":"1980","journal-title":"Gastroenterology"},{"key":"10.1016\/j.medcli.2013.05.035_bib0145","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2337\/diab.36.5.673","article-title":"Somatostatin impairs clearance of exogenous insulin in humans","volume":"36","author":"Ipp","year":"1987","journal-title":"Diabetes"},{"key":"10.1016\/j.medcli.2013.05.035_bib0150","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1210\/jc.80.6.1789","article-title":"Somatostatin enhances insulin-stimulated glucose uptake in the perfused human forearm","volume":"80","author":"M\u00f8ller","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.medcli.2013.05.035_bib0155","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1046\/j.1365-2265.2003.01876.x","article-title":"Glucose homeostasis in acromegaly: Effects of long-acting somatostatin analogues treatment","volume":"59","author":"Baldelli","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.medcli.2013.05.035_bib0160","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1210\/jc.82.2.518","article-title":"Effect of different dopaminergic agents in the treatment of acromegaly","volume":"82","author":"Colao","year":"1997","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775313004478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775313004478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,23]],"date-time":"2019-07-23T09:21:33Z","timestamp":1563873693000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775313004478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0025775313004478"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2013.05.035","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}